In a recent article for Drug Store News, Chip Davis, President and CEO for the Association of Accessible Medicines, discusses the important role pharmacists will play in the education and adoption of biosimilars.
“As trusted partners for patients, pharmacists play a critical role. They are and will continue to be a critical voice in educating patients on biosimilar medicines” says Davis. Pharmacists are in a unique position to discuss biosimilar availability and options with patients and doctors alike.
Adoption of biosimilars is something everyone should be concerned about. Estimates from various economic impact studies pin the projected savings from $44 billion on the low end to as high as $250 billion over 10 years and $378 billion over 20 years. While statistical assumptions for each analysis vary, experts agree on the transformative potential and significant savings from biosimilars.